SERO Serologicals (MM)

OCEANSIDE, Calif., Jan. 17 /PRNewswire-FirstCall/ -- SeraCare Life Sciences, Inc. (NASDAQ:SRLSENASDAQ:SRLS), today announced that it has closed its previously announced acquisition of the Milford, MA diagnostic manufacturing facilities and product lines of the Celliance subsidiary of Serologicals Corporation (NASDAQ:SERO). Michael F. Crowley, Jr., President and CEO of SeraCare Life Sciences said, "We are pleased to have completed this acquisition as we expect it will increase our portfolio of products in the areas of molecular diagnostic reagents, diagnostic intermediates and substrates. In connection with this acquisition, we have assumed the lease on Celliance's state of the art manufacturing, storage and distribution facility located near our West Bridgewater manufacturing site. We believe the proximity of these two diagnostic manufacturing facilities will allow us to achieve synergies in the areas of manufacturing, staffing and distribution." About SeraCare Life Sciences SeraCare Life Sciences Inc. is a manufacturer and provider of biological products and services to diagnostic, therapeutic, drug discovery, and research organizations. The Company's offerings include plasma-based therapeutic products, diagnostic products and reagents, cell culture products, specialty plasmas, in vitro stabilizers, and the SeraCare BioBank(TM), a proprietary database of medical information and associated blood, plasma, DNA and RNA samples. Headquartered in Oceanside, CA, SeraCare conducts business throughout the world, and is traded on the NASDAQ national stock market under the symbol SRLSE. For additional information about SeraCare Life Sciences Inc., please visit the Company's web site at http://www.seracare.com/. Safe Harbor For Forward-Looking Statements Certain statements contained in this press release may be deemed to be forward-looking statements under federal securities laws, and the Company intends that such forward looking statements be subject to the safe harbor created thereby. Such statements include the Company's expectation that (i) the asset acquisition will increase its portfolio of products in the areas of molecular diagnostic reagents, diagnostic intermediates and substrates, and (ii) the proximity of the Celliance manufacturing facility and the Company's West Bridgewater manufacturing facility will allow the Company to achieve efficiencies in the areas of manufacturing, staffing and distribution. The Company cautions that these statements are qualified by important factors that could cause actual results to differ materially from those reflected by the forward- looking statements. Such factors include, but are not limited to (i) the ability of the parties to the acquisition agreement to timely satisfy each of the conditions to closing, (ii) the Company's ability to integrate the acquired operations into its own, (iii) the Company's ability to retain the customers from the acquired operations, and (iv) the Company's access to adequate blood and plasma raw materials on terms consistent with its existing contracts. Information on these and additional factors that could affect the Company and its financial results is included in the Company's report on Form 10-K for the year ended September 30, 2004 filed with the Securities and Exchange Commission (SEC) as well as the Company's other public filings with the SEC. The Company undertakes no obligation to publicly update or revise any forward looking statements, whether as a result of new information, future events or otherwise. DATASOURCE: SeraCare Life Sciences, Inc. CONTACT: Tim Ryan of The Trout Group, +1-212-477-9007, ext. 24, or Web site: http://www.seracare.com/

Copyright